We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN) Discontinues Brazikumab Development
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) announced the discontinuation of studies on its monoclonal antibody targeting IL23, brazikumab. The candidate was being studied for two indications, Crohn’s disease (CD) and ulcerative colitis (UC), under the inflammatory bowel disease (IBD) development program.
A phase IIb/III INTREPID study was evaluating brazikumab for treating CD and a phase II EXPEDITION study for treating UC. The program also included the respective open-label extension studies of the INTREPID and EXPEDITION studies.
AstraZeneca cited evolving competitive landscape and the delayed regulatory timeline of brazikumab as reasons for discontinuing the IBD development program on brazikumab. The company further elaborated that the impact of regulatory delays on brazikumab’s development was irrecoverable due to global events.
In the year so far, shares of AstraZeneca have climbed 7.7% against the industry’s 1.9% decline.
Image Source: Zacks Investment Research
We would like to remind the investors that in 2016, AstraZeneca first entered into a licensing agreement with Allergan, now part of AbbVie (ABBV - Free Report) , for the global rights to brazikumab. However, in early 2020, AstraZeneca announced that it will regain the global rights to brazikumab from Allergan (now AbbVie).
The termination of the agreement with Allergan was due to Allergan’s decision to divest brazikumab in connection with its merger with AbbVie. AbbVie was contributing to the ongoing funding of brazikumab studies, but this funding will now end.
AstraZeneca’s another recent pipeline setback was the ALXN1840 program. The company announced that it is discontinuing the ALXN1840 program in Wilson Diseases based on the feedback from regulatory authorities which reviewed data from the phase III FoCus study and two phase II mechanistic studies.
In the past 90 days, the Zacks Consensus Estimate for Novartis’ 2023 earnings per share has increased from $6.52 to $6.67. In the year so far, shares of Novartis have increased 6.1%.
NVS beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.15%.
In the past 90 days, the Zacks Consensus Estimate for Akero Therapeutics’ 2023 loss per share has narrowed from $3.46 to $2.78. In the year so far, shares of Akero Therapeutics have fallen by 18.7%.
AKRO beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 7.96%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN - Free Report) announced the discontinuation of studies on its monoclonal antibody targeting IL23, brazikumab. The candidate was being studied for two indications, Crohn’s disease (CD) and ulcerative colitis (UC), under the inflammatory bowel disease (IBD) development program.
A phase IIb/III INTREPID study was evaluating brazikumab for treating CD and a phase II EXPEDITION study for treating UC. The program also included the respective open-label extension studies of the INTREPID and EXPEDITION studies.
AstraZeneca cited evolving competitive landscape and the delayed regulatory timeline of brazikumab as reasons for discontinuing the IBD development program on brazikumab. The company further elaborated that the impact of regulatory delays on brazikumab’s development was irrecoverable due to global events.
In the year so far, shares of AstraZeneca have climbed 7.7% against the industry’s 1.9% decline.
Image Source: Zacks Investment Research
We would like to remind the investors that in 2016, AstraZeneca first entered into a licensing agreement with Allergan, now part of AbbVie (ABBV - Free Report) , for the global rights to brazikumab. However, in early 2020, AstraZeneca announced that it will regain the global rights to brazikumab from Allergan (now AbbVie).
The termination of the agreement with Allergan was due to Allergan’s decision to divest brazikumab in connection with its merger with AbbVie. AbbVie was contributing to the ongoing funding of brazikumab studies, but this funding will now end.
AstraZeneca’s another recent pipeline setback was the ALXN1840 program. The company announced that it is discontinuing the ALXN1840 program in Wilson Diseases based on the feedback from regulatory authorities which reviewed data from the phase III FoCus study and two phase II mechanistic studies.
AstraZeneca PLC Price and Consensus
AstraZeneca PLC price-consensus-chart | AstraZeneca PLC Quote
Zacks Rank and Stocks to Consider
AstraZeneca currently has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the overall medical sector are Novartis (NVS - Free Report) and Akero Therapeutics (AKRO - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Novartis’ 2023 earnings per share has increased from $6.52 to $6.67. In the year so far, shares of Novartis have increased 6.1%.
NVS beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.15%.
In the past 90 days, the Zacks Consensus Estimate for Akero Therapeutics’ 2023 loss per share has narrowed from $3.46 to $2.78. In the year so far, shares of Akero Therapeutics have fallen by 18.7%.
AKRO beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 7.96%.